What Has Been the Progress and Growth of the Male Hypogonadism Market in Recent Years?
The male hypogonadism market has seen considerable growth due to a variety of factors.
• Over the past few years, the market size of male hypogonadism has seen substantial growth. The sector's value is set to increase from $3.75 billion in 2024 to $3.99 billion in 2025, registering a compound annual growth rate (CAGR) of 6.3%. This growth during the historical period can be credited to factors such as the aging population, increased awareness and diagnosis, lifestyle conditions, chronic diseases, and the behavior of seeking treatments.
How Does the Forecast Look for the Male Hypogonadism Market in the Coming Years?
The Male Hypogonadism market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated to witness robust growth in the coming years, the male hypogonadism market is projected to expand to $5.08 billion in 2029 with a compound annual growth rate (CAGR) of 6.2%.
The progression during the projected period can be linked to increased awareness, the incidence of conditions related to lifestyle, therapeutic innovations, attention on men's wellbeing, telemedicine, and more accessible healthcare. The forecasted period is likely to see growing concern for psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, market widening in developing nations, combined research efforts, and a focus on prolonged safety and monitoring.
What Are The Leading Drivers Of Growth In The Male Hypogonadism Market?
The rise in infertility rates is anticipated to boost the expansion of the male hypogonadism market in the future. Infertility is a condition that affects the reproductive system of males or females, marked by the inability to conceive after a year or more of regular, unprotected sexual intercourse. Male hypogonadism, which might result in reduced sperm production and infertility, is a possible root of male infertility. Consequently, the growing frequency of male infertility is projected to fuel the male hypogonadism market's growth. For example, the Office for National Statistics, a government department in the UK, reported in February 2024 that the total fertility rate (TFR) rose to 1.49 children per woman in 2022, up from 1.55 in 2021. As such, the ascent in the infertility rate is propelling the male hypogonadism market's growth.
How Are The Segments Defined Within The Global Male Hypogonadism Market?
The male hypogonadism market covered in this report is segmented –
1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types
2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries
3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy
Subsegments:
1) By Klinefelter's Syndrome: 47,XXY Syndrome, Other Variants
2) By Kallmann Syndrome: Isolated Kallmann Syndrome, Syndromic Kallmann Syndrome
3) By Pituitary Disorders: Hypopituitarism, Pituitary Tumors, Other Pituitary Disorders
4) By Other Types: Androgen Insensitivity Syndrome, Testicular Dysgenesis Syndrome, Genetic Mutations And Disorders
Pre-Book The Male Hypogonadism Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Male Hypogonadism Market?
A key trend observed gaining traction in the male hypogonadism market is the innovation of new products. To maintain their market position, businesses in the male hypogonadism industry are developing new products. For instance, in June 2022, Halozyme, a biotechnology company based in the US, introduced Tlando, a new oral treatment for testosterone replacement therapy for men suffering from hypogonadism. Tlando, a drug that contains testosterone, has the unique distinction of being the first orally-administered testosterone therapy to receive FDA approval. The drug is used to treat adult men whose testosterone levels are low or nonexistent due to certain medical conditions.
Who Are the Key Players In The Male Hypogonadism Market?
Major companies operating in the male hypogonadism market include:
• Pfizer Inc.
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc.
• Merck & Co. Inc.
• Ferring Pharmaceuticals
• Finox Biotech AG
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Perrigo Company plc
• IBSA Institut Biochimique SA
• Sun Pharmaceutical Industries Limited
• Glenmark Pharmaceuticals Limited
• Antares Pharma Inc.
• Zydus Cadila LLC
• Besins Healthcare Ltd.
• Clarus Therapeutics Holdings Inc.
• Foresee Pharmaceuticals Co. Ltd.
• Lipocine Inc.
• Myovant Sciences Ltd.
• Sandoz International GmbH
• Shionogi & Co. Ltd.
• TherapeuticsMD Inc.
• Viking Therapeutics Inc.
What Is The Most Dominant Region In The Male Hypogonadism Market?
North America was the largest region in the male hypogonadism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
